HUMA - Latest News
Humacyte, Inc. (HUMA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $177.1M. Beta to the broader market is 2.31.
The article list below shows the most recent HUMA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent HUMA Headlines
Humacyte Q1 Earnings Call Highlights
marketbeat.com - May 13, 2026
Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0. 5 million and outlined a series of commercial, clinical and cost-reduction init
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
zacks.com - May 13, 2026
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com - May 13, 2026
- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
globenewswire.com - May 12, 2026
- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer -
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
zacks.com - May 8, 2026
Humacyte, Inc. (HUMA) closed at $1.
How News Affects HUMA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track HUMA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked HUMA news questions
- What is the latest HUMA news headline?
- The most recent HUMA headline (May 13, 2026) is "Humacyte Q1 Earnings Call Highlights". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the HUMA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What HUMA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual HUMA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.